Combining Psychotherapy and Medication Versus Either Alone for PTSD
A patient beginning prolonged exposure therapy wants to also start an SSRI, assuming combining treatments can only help. Whether the added burden of two treatments at once is actually worth it — and whether an SSRI might blunt the very fear-extinction learning exposure therapy depends on — is genuinely unsettled.
D.V. is a 28-year-old man, a former rideshare driver who developed PTSD after being carjacked at gunpoint eighteen months ago and has since switched to warehouse work he describes as "the first job where I don't have to watch every car that pulls up behind me." He has never taken a psychiatric medication, has no other medical history, and has just been accepted into a prolonged exposure program with a therapist he specifically requested after a friend's recommendation.
He arrives at this visit assuming that starting an SSRI alongside the therapy is simply the more thorough option — more treatment, more improvement, with little downside. That assumption is reasonable-sounding but not well supported by the actual literature: most large PTSD medication trials and most large psychotherapy trials were run separately, evaluating each modality on its own, and the handful of studies that have directly tested combination against monotherapy have generally found little to no added benefit from combining them over prolonged exposure alone. There is also a more specific theoretical concern that cuts the other way entirely: SSRIs affect the same serotonergic circuitry involved in fear extinction learning, the actual mechanism prolonged exposure depends on to work, and some data suggests starting an SSRI during active exposure treatment may blunt or slow that extinction learning rather than simply adding to it. Neither point is settled enough to give D.V. a confident answer — what is genuinely known is that "more treatment" is not automatically the safer or more effective assumption it sounds like.
At the intake visit
I want to correct the "more must be better" assumption directly and honestly, because it is the most common reason patients ask for this. The actual trial evidence for combination over prolonged exposure alone is thin, and given that he has real, motivated access to a therapist he specifically sought out, I would let the therapy run on its own first rather than add a variable with an uncertain, possibly even counterproductive interaction.
I'd be careful not to overstate the extinction-blunting concern as settled, though — it comes from a smaller and more mixed body of evidence than the "no added benefit" finding does, and for a patient with meaningful baseline distress, some clinicians would still reasonably start an SSRI concurrently rather than ask him to tolerate untreated symptoms through the hardest weeks of exposure work.
If his baseline symptoms were severe enough to threaten his ability to engage with exposure sessions at all, I would weigh this differently — he is functional and motivated, which is part of why I can support holding medication for now.
Given that he is functioning well enough to start PE on his own terms, the honest recommendation is to begin therapy alone and revisit medication specifically if his symptoms are not improving by the midpoint of the course — not because combination is wrong in principle, but because starting both at once would make it impossible to know what actually helped him if he does improve.
D.V. began prolonged exposure therapy alone, with an explicit plan to reassess medication at the program's midpoint if his symptoms have not meaningfully improved.
Genuinely unresolved and named as such: whether starting an SSRI at the outset would have helped, hurt, or made no difference to his extinction learning was not something this visit could answer — the plan was built around getting real information from his actual response, not around either clinician's prediction winning out.